The relative contribution of these mechanisms to FAP-RLT efficacy remains unexplored, with responsiveness potentially varying based on factors such as the type of cells expressing FAP, tumor architecture, FAP-radioligand characteristics, and tumor biology. Here, FAP is linked to neoplasm.